Table 3—

HbA1c, age, duration of diabetes, and percentage male in groups of patients with diabetes who have had hypoglycemic (hypo) events and those who have not had hypoglycemia (no hypo)

TreatmentnHbA1c (%)Age (years)Duration of diabetes (years)BMI (kg/m2)Sex (% male)
Type 1: no hypoInsulin9087.93 (7.76–8.10)32.8 (31.8–33.8)16.7 (15.8–17.7)24.7 (24.4–25.0)56.1
Type 1: hypoInsulin697.77 (7.29–8.25)37.7 (34.1–41.3)20.7 (17.7–23.7)25.0 (24.3–25.7)66.7
P0.5330.0090.0130.5570.078
Type 2: no hypoInsulin8358.23 (8.09–8.37)63.2 (62.4–64.1)11.8 (11.2–12.4)30.1 (29.4–30.8)47.7
Type 2: hypoInsulin667.87 (7.47–8.28)66.6 (63.5–69.6)13.5 (11.3–15.8)26.7 (25.7–27.7)47.0
P0.0970.0380.137<0.0010.914
Type 2: no hypoSulphonylurea tablets2,8007.16 (7.08–7.23)65.4 (65.0–65.9)6.3 (6.0–6.5)29.6 (29.5–29.7)52.2
Type 2: hypoSulphonylurea tablets238.00 (7.10–8.91)65.0 (59.1–70.9)7.2 (4.3–10.0)28.1 (26.7–29.5)47.8
P0.0640.8840.5170.1220.687
All diabetes: no hypoAll therapies8,4957.19 (7.14–7.24)62.3 (61.9–62.6)8.9 (8.6–9.2)29.0 (28.9–29.1)52.6
All diabetes: hypoAll therapies1607.85 (7.57–8.14)53.8 (50.8–56.9)15.6 (13.8–17.4)26.1 (25.5–26.7)55.6
P<0.001<0.001<0.001<0.0010.454
  • Data are mean (95% CI). The study groups include patients with type 1 diabetes, those with type 2 diabetes treated with insulin, and those with type 2 diabetes treated with tablets. Additionally patients have been analyzed as an overall combined group.